DGIdb - IFOSFAMIDE Drug Record

IFOSFAMIDE chembl:CHEMBL1024 ApprovedAntineoplasticImmunotherapy

Alternate Names:

MITOXANA
Z-4942
IFSOFAMIDE
IFEX
NSC-109724
IFOSFAMIDE
MJF-9325
ISOSFAMIDE
IPHOSPHAMIDE
ISOFOSFAMIDE
IFOSFAMIDA
ISOPHOSPHAMIDE
3-(2-CHLOROETHYL)-2-((2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE
IFEX®
IFOSFAMIDUM
HOLOXAN®
chembl:CHEMBL1024
pubchem.compound:3690
chemidplus:3778-73-2
rxcui:5657
drugbank:01181

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	1988
FDA Approval	1988
Drug Class	small molecule
Drug Indications	Antineoplastic Agents

(3 More Sources)

Publications:

Ohnstad et al., 2013, Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma., Cancer
Heits et al., 1997, Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia., Eur. J. Haematol.
Preuss et al., 1996, Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs., Int. J. Cancer
Zielińska et al., 2005, Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children., J. Pediatr. Hematol. Oncol.
Komatsu T et al., 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4., Drug Metab Dispos
Torchin CD et al., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes., Drug Metab Dispos
Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab
Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab
Kimber-Trojnar Z et al., 2003, Perspectives of losigamone in epilepsy treatment., Pol J Pharmacol
Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
Gehrmann et al., 2002, Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels., Biol. Chem.
Harmsen et al., 2009, Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor., Cancer Chemother. Pharmacol.

IFOSFAMIDE CYP2A6

Interaction Score: 2.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11038165 8886611 19702528 19442086 14704462 12386121

Sources:
PharmGKB
IFOSFAMIDE MGMT

Interaction Score: 0.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8621235

Sources:
NCI
IFOSFAMIDE IL6

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9260581

Sources:
NCI
IFOSFAMIDE DNMT1

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
None found

Sources:
TdgClinicalTrial TEND
IFOSFAMIDE HSPA4

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12530536

Sources:
NCI
IFOSFAMIDE CYP2B6

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11470993 17638512

Sources:
PharmGKB
IFOSFAMIDE GSTP1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16282887

Sources:
NCI
IFOSFAMIDE NR1I2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18839173

Sources:
PharmGKB
IFOSFAMIDE TP53

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Doxorubicin + Ifosfamide

Indication/Tumor Type sarcoma

Response Type sensitive

PMIDs:
23165797

Sources:
JAX-CKB

TEND: IFOSFAMIDE
- Version: 01-August-2011
Alternate Names:

IFOSFAMIDE Primary Drug Name

Drug Info:

Year of Approval 1988

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: IFOSFAMIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents

Drug Class small molecule

FDA Approval 1988

Publications:

NCI: IFOSFAMIDE

Version: 14-September-2017

Alternate Names:

C564 NCI drug code

Drug Info:

Publications:

Preuss et al., 1996, Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs., Int. J. Cancer

Zielińska et al., 2005, Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children., J. Pediatr. Hematol. Oncol.

Gehrmann et al., 2002, Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels., Biol. Chem.

PharmGKB: ifosfamide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos

Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab

Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab

JAX-CKB: Ifosfamide
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Ohnstad et al., 2013, Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma., Cancer
TTD: Ifosfamide
- Version: 2020.06.01
Alternate Names:

D02TLO TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1024
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

combination therapy	Doxorubicin + Ifosfamide
Indication/Tumor Type	sarcoma
Response Type	sensitive

Novel drug target	Established target
Trial Name	-

IFOSFAMIDE Drug Record

IFOSFAMIDE chembl:CHEMBL1024 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11038165 8886611 19702528 19442086 14704462 12386121

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8621235

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9260581

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: None found

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12530536

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11470993 17638512

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16282887

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18839173

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Doxorubicin + Ifosfamide Indication/Tumor Type sarcoma Response Type sensitive

PMIDs: 23165797

Sources: JAX-CKB

TEND: IFOSFAMIDE

Alternate Names: IFOSFAMIDE Primary Drug Name

Drug Info: Year of Approval 1988 Drug Class antineoplastic agents

Publications:

TdgClinicalTrial: IFOSFAMIDE

Alternate Names:

Drug Info: Drug Indications Antineoplastic Agents Drug Class small molecule FDA Approval 1988

Publications:

NCI: IFOSFAMIDE

Alternate Names: C564 NCI drug code

Drug Info:

PharmGKB: ifosfamide

Alternate Names:

Drug Info:

JAX-CKB: Ifosfamide

Alternate Names:

Drug Info:

Publications: Ohnstad et al., 2013, Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma., Cancer

TTD: Ifosfamide

Alternate Names: D02TLO TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1024

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
11038165 8886611 19702528 19442086 14704462 12386121

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8621235

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9260581

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
None found

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
12530536

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11470993 17638512

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16282887

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18839173

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Doxorubicin + Ifosfamide

Indication/Tumor Type sarcoma

Response Type sensitive

PMIDs:
23165797

Sources:
JAX-CKB

Alternate Names:

IFOSFAMIDE Primary Drug Name

Drug Info:

Year of Approval 1988

Drug Class antineoplastic agents

Drug Info:

Drug Indications Antineoplastic Agents

Drug Class small molecule

FDA Approval 1988

Alternate Names:

C564 NCI drug code

Publications:

Ohnstad et al., 2013, Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma., Cancer

Alternate Names:

D02TLO TTD Drug ID